PDS Biotechnology is a biopharmaceutical company developing novel cancer immunotherapies and vaccines for infectious diseases.
PRESS RELEASE: August 24, 2016 PDS Announces Agreement with FDA on Phase 2 Clinical Path for PDS0101
PRESS RELEASE: April 13, 2016 PDS BIOTECHNOLOGY REPORTS POSITIVE Phase I/IIA STUDY RESULTS FOR PDS0101 IMMUNOTHERAPY FOR HPV-RELATED CANCERS
PRESS RELEASE: February 9, 2016 PDS AND NCI SIGN PHASE 2 CLINICAL CO-DEVELOPMENT AGREEMENT FOR PROSTATE, BREAST AND HPV-CANCERS
PRESS RELEASE: January 19, 2016 IMMUNOTHERAPY COMPANY PDS BIOTECHNOLOGY STRENGTHENS SENIOR MANAGEMENT TEAM, ADDS TWO DRUG DEVELOPMENT EXECUTIVES